| OAB | Overactive bladder |
| UTI | Urinary Tract Infection |
| GLP-1 RA | Glucagon-Like Peptide-1 Receptor Agonist |
| BTX-A | OnabotulinumtoxinA |
| KM | Kaplan–Meier |
| BMI | Body Mass Index |
| ARC | Arcuate Nucleus |
| AP | Area Postrema |
| NTS | Nucleus Tractus Solitarius |
| POMC | Pro-Opiomelanocortin |
| NPY | Neuropeptide Y |
| AgRP | Agouti-Related Peptide |
| SMD | Standardized Mean Difference |
| HR | Hazard Ratio |
| FDA | U.S. Food and Drug Administration |
| PCOS | Polycystic Ovary Syndrome |
| AUA | American Urological Association |
| EAU | European Association of Urology |
| ICD-10-CM | International Classification of Diseases, 10th Revision, Clinical Modification |
| EHR | Electronic Health Record |
| IRB | Institutional Review Board |
| VA | Veterans Affairs (used in context of drug classes |
| IQR | Interquartile Range |
| CI | Confidence Interval |
| TriNetX | A federated real-world data research network/platform |